

Index

- 510(k)
 – abbreviated 203
 – *de novo* 203
 – notification 202f.
 – pre-market notification 202
 – review procedure 203
 – special 203
 – submission 204
- a**
- abbreviated new animal drug application (ANADA) 159
 abbreviated new drug application (ANDA) 113, 159
 absorption 62f.
 acceptable daily intake (ADI) 137
 active implantable medical device (AIMD) 167, 187
 active pharmaceutical ingredient (API) 209
 – good manufacturing practice (GMP) 211
 – manufacturer 210
 – manufacturing site 242
 ADME 62
 adverse event reporting 87
 advertising 262
 air quality 219
 Ames test 66
 Anatomical Therapeutic Chemical (ATC) classification system 45f.
 animal and plant health inspection service (APHIS) 35
 animal study
 – *in-vivo* 64
 animal treatment 154
 annual report 94
 annual safety report 88
 appendix 104
 application dossier 97
 asthma inhaler 18
 audit finding 248
 audit master recall 223
 authorisation
 – generic drug 158
 – medical device 187ff.
 – veterinary medicine 131ff.
 azidothymidine (AZT, zidovudine) 47
- b**
- bacterial reverse-mutation test 66
 benefit 2
 bioavailability 64
 – *in-vitro* 64
 – *in-vivo* 64
 bioequivalence 64
 bioinformatics 50
 biologics license application (BLA) 113
 biopharmaceutical 44
 biotech product
 – quality 68
 breath test 19, 45
- c**
- carcinogenicity study 67
 case report form (CRF) 87
 CE mark 170
 cell
 – membrane 53
 Center for Biologics Evaluation and Research (CBER) 34, 89
 Center for Devices and Radiological Health (CDRH) 35, 192
 Center for Drug Evaluation and Research (CDER) 34, 89
 Center for Veterinary Medicine (CVM) 35, 135
 change

- EU system for processing 154
 - major 157
 - minor 157
 - moderate 157
 - characterisation 103
 - chemistry, manufacturing and control
 - development (CMC) 67f.
 - chromosomal damage 66
 - cimetidine 48
 - classification
 - device 173ff.
 - panel 173
 - clean room 220
 - cleaning in place (CIP) 229
 - cleaning validation 229
 - clinical investigation 188f.
 - clinical study report 105
 - clinical trial 73ff.
 - amendment 87
 - application (CTA) 84
 - design 76
 - EU 78, 134
 - monitoring 88
 - phase I 74
 - phase II 74
 - phase II 75
 - US 89ff., 135
 - veterinary medicine 131ff.
 - code of federal regulations (CFR) 14
 - chapter 21 (21 CFR) 14, 211ff.
 - codex alimentarius 137
 - combination product 161
 - Committee on Herbal Medicinal Products (HMPC) 30
 - Committee for Medicinal Products for Human Use (CHMP) 30, 119
 - Committee for Orphan Medicinal Products (COMP) 30, 150
 - Committee for Veterinary Medicinal Products (CVMP) 30, 138
 - common technical document (CTD) 97ff.
 - electronic (eCTD) 99
 - community authorisation 114
 - competent authority clinical trial application 84f.
 - competent authority notification 201
 - computer system validation 226
 - concept of potency and effectiveness 62
 - conditional approval 153
 - conformity assessment procedure 195
 - contact
 - duration 172
 - control 103
 - corrective action 25
 - preventive action (CAPA) 248
 - crossover trial design 77
- d**
- decision-making process 120
 - Declaration of Helsinki 78
 - design
 - change 185
 - control 180
 - development 180
 - input 182
 - output 182
 - qualification (DQ) 225
 - review 183
 - validation 183
 - verification 183
 - designation 154
 - development 178f.
 - device, *see also* medical device 17
 - certification 197
 - class I 176
 - class II 177
 - class III 178
 - classification 170ff.
 - development 178f.
 - GMP requirement 231
 - humanitarian device exemption (HDE) 206
 - humanitarian use (HUD) 206
 - investigational use 193
 - labelling 193, 206
 - master record (DMR) 234
 - new 178
 - placing on the market 194ff.
 - oversight 262
 - pre-market approval (PMA) 205
 - registration of person (US) 240
 - dietary supplement 16
 - diffusion 63
 - directive 5ff.
 - good manufacturing practice (GMP) 210ff.
 - distribution 62
 - documentation 24
 - pharmaceutical manufacture 221
 - technical 199
 - dossier structure 143
 - double-blind trial 77
 - drug 17
 - authorisation process 149ff.
 - categorisation 43
 - change 154
 - characteristics 52
 - delivery 52
 - development 50f.
 - discovery 43ff.

- establishment registration 243
- generic 158
- good manufacturing practice (GMP) 209ff.
- investigational 89ff.
- large molecule 53
- manufacturing facility 219
- master file 104
- mode of action 44
- new 44
- non-authorised 154
- over-the-counter (OTC) 162
- oversight 253
- producer registration (US) 241
- stability 55
- substance 104

e

- EC type-examination 197
- EC (self) declaration of conformity 199
- EC verification 199
- efficacy (E) 2, 38
- endosome 53
- enterprise resource planning (ERP) system 227
- enzyme 61
- equipment 25, 213
 - validation 225
- ethics committee 85
- evaluation
 - EU 187
 - US 191
- European Union (EU)
 - change system for processing 154
 - clinical trial 78, 134
 - evaluation 187
 - GMP directive 213
 - legislative process 4
 - market vigilance 263
 - marketing authorisation application 111
 - medical device 167
 - medical device evaluation 187
 - medical device regulatory strategy 167
 - medicinal product 237
 - module 110
 - person registration for placing medical device on the market 240
 - regulation 158, 210
 - review process 114ff.
 - rules governing medicinal products 79
 - submission 114
 - veterinary medicine 138
- EUDAMED 201
- EudraCTdatabase 85
- EudraGMP network 252

- EudraLex collection 27
- EudraNet system 27
- European Commission 27
- European Committee for Electrotechnical Standardization (CENELEC) 168
- European Committee for Standardization (CEN) 168
- European Databank 201
- European Directorate for the Quality of Medicines and Healthcare (EDQM) 36
- European Medicines Agency (EMA) 29, 119, 238
 - accelerated review 151
 - major variation 155
- European Norm (EN) 168
- European Pharmacopoeia (Ph.Eur.) 7
- European public assessment report (EPAR) 121
- examination 197
- excipient 54
- excretion 62f.
- extension application 155
- Exubera® 53

f

- facility 25
 - validation 225
- factorial trial design 78
- failure mode effect analysis (FMEA) 184
- fast-track product 152
- fault tree analysis (FTA) 184
- field safety action template 272
- field safety corrective action (FSCA) 264
- field safety notice (FSN) 268
- Food & Agriculture Organisation (FAO) 137
- food and drugs administration (FDA) 11, 32
 - communication 94
- full
- functional food 16

g

- Gantt chart 181
- general operating procedure (GOP) 24
- generally recognised as safe and effective (GRASE) 162
- generic drug 158
- genetically modified organism (GMO) 113
- genotoxicity study 66
- Global Harmonisation Task Force (GHTF) 39, 264
- good automated manufacturing practice (GAMP) 226
- good clinical practice (GCP) 78
 - veterinary medicine 131

good laboratory practice (GLP) 22, 69
 good manufacturing practice (GMP) 22,
 209ff.
 – core (US) 214
 – current (cGMP) (US) 212
 – device requirement 231
 – directive (EU) 213
 – drug 209
 – report template 250
 guidance document 6

h

HAZOP 226
 health food 16
 heating, ventilation and air conditioning
 (HVAC) 215
Helicobacter pylori 19, 45ff.
 hepatitis B 48
 herbal medicine
 – traditional 162
 high-efficiency particulate air (HEPA) filter
 215
 histamine receptor 48
 homeopathic remedy 16, 161
 human immunodeficiency virus (HIV) 47
 human medicine, *see* medicine
 humanitarian device exemption (HDE) 206
 humanitarian use device (HUD) 206

i

ICH, *see* International Conference on
 Harmonisation
 identity 103
 impact
 – body 172
in vitro diagnostics (IVD) 167, 188
in-vitro test with mammalian cell 66
in-vivo test in rodent 66
 index of legally marketed non-approved
 drugs 154
 indexing 154
 indications for use statement 2
 information amendment 94
 informed consent 82
 inhibitor
 – competitive 61
 – non-competitive 61
 inspection 242
 – quality system 249
 – technique 245
 installation qualification (IQ) 225
 institutional review board (IRB) 89ff.
 insulin
 – inhalable 53

intended use statement 2
 International Conference on Harmonisation
 (ICH) 36, 97
 – GMP guideline for API manufacture 216f.
 – harmonisation process 38
 – multidisciplinary guideline 58
 International Electrotechnical Commission
 (IEC) 168
 International Federation of Pharmaceutical
 Manufacturers Association (IFPMA) 38
 international harmonisation bodies 36
 International Standards Organisation (ISO)
 168
 – ISO 9001 170
 invasiveness
 – degree 172
 investigation
 – abbreviated requirement 192
 investigational device exemption (IDE) 191ff.
 – application 194
 investigational drug
 – labelling 95
 investigational new animal drug (INAD) 135
 investigational new drug application (IND)
 89
 – treatment 152
 investigational medicinal product 82
 – dossier (IMPd) 82
 investigator 81
 investigator's brochure (IB) 80
 IVD (*in-vitro* diagnostic) medical device, *see*
 medical device

j

Joint Expert Committee on Food Additives
 (JECFA) 137

l

labelling
 – device for investigational use 193
 – requirement 200
 legal text 5
 legislation
 – basic 7
 – EU 7
 – scope 16
 – US 11
 legislative process 3f.
 lethal concentration (LC₅₀) value 65
 lethal dose (LD₅₀) value 65
 licensing requirement
 – additional 242
 lowest observed (adverse) effect level (LO(A)
 EL) 137

m

major variation 155
 manufacture of investigational medicinal product 82
 manufacturer
 – incident report form 265
 – registration 237
 manufacturing authorisation 237
 – renewal 258
 manufacturing change supplement 156
 manufacturing process 103
 market
 – placing medical device 240
 market vigilance 22, 253ff.
 – EU 263
 marketing authorisation 97ff., 142
 – holder (MAH) 241
 maximum residue limit (MRL) 136f.
 – dossier 141
 medical device (MD), *see also* device 17ff., 167ff.
 – evaluation (EU) 187
 – evaluation (US) 191
 – IVD (*in-vitro* diagnostic) 19
 – regulatory strategy (EU) 167
 – regulatory strategy (US) 173
 – reporting 272
 – vigilance (US) 271
 medical use product
 – well-established 161
 medicinal product
 – EU 237
 – wholesale direction 238
 medicine
 – human 43
 – prescription-only (POM, Rx) 43
 – veterinary, *see* veterinary medicine
 membrane
 – drug delivery 53
 metabolism 62f.
 methods validation 227
 minor use and minor species (MUMS)
 amendment 153
 minor variation 156
 mission statement 29
 mode of action 172
 model
 – *in-vitro* 64
 module 101ff.
 module structure 101
 monitoring of trial 88
 multidisciplinary (M) 38
 mutual recognition procedure
 123

n

national authorisation 121
 – decentralised procedure 121
 National Committee for Clinical Laboratory Standard (NCCLS) 170
 national legislative process 3
 new animal drug application (NADA) 144
 new drug
 – approval 153
 new drug application (NDA) 113
 – review process 126
 new drug therapy 151
 no observed (adverse) effect level (NO(A)EL) 137
 non-clinical safety study for the conduct of human clinical trials for pharmaceuticals 58
 non-clinical study 57ff.
 – objectives and timing 57
 – report 105
 notice of claimed investigational exemption (NCIE) 135
 notification 202f.
 – 510(k) pre-market 202
 notified body 32

o

Office International des Epizooties (OIE) 39
 Office of Combination Products (OCP) 35
 Office of Orphan Products Development (OOPD) 150
 Office of Regulatory Affairs (ORA) 34
 Official Medicines Control Laboratory (OMCL) 36
 omeprazole 48
 orphan drug 149
 – criteria 150
 over-the-counter (OTC) 43
 – drug 162

p

package leaflet 112
 packaging 104
 paediatric application 152
 Paediatric Committee (PDCCO) 30
 parallel group design 77
 peptic ulcer 48
 performance
 – evaluation 190
 – qualification (PQ) 225
 periodic safety update report (PSUR) 256
 person
 – qualified 254

- registration for placing medical device on the market (EU) 240
 - personnel 23
 - good manufacturing practice (GMP) 212
 - pharmaceutical current good manufacturing practice (cGMP) 246f.
 - Pharmaceutical Inspection Cooperation Scheme (PICS) 40, 246
 - pharmacodynamic study 59
 - pharmacokinetic study 59ff.
 - pharmacological study 58f.
 - pharmacopoeia 7
 - pharmacovigilance 254ff.
 - pinocytosis 53
 - placebo effect 77
 - placing on the market 194ff.
 - registration of person 240
 - Plan-Do-Check-Act (PDCA) 170f.
 - plasma master file 124
 - post-market surveillance 273f.
 - pre-clinical study 130
 - pre-market approval (PMA) 203ff.
 - device 205
 - pre-market notification 202
 - prescription drug
 - human 44
 - prescription status 43
 - preventive action 25
 - principal activity 29
 - process
 - validation 225
 - processing change 156
 - producer of drug/device
 - registration (US) 241
 - product
 - authorisation (PA) 241
 - development 21
 - manufacture 21
 - quality assurance 199
 - recall 223
 - safety 2
 - production 222
 - quality assurance 199
 - promotion 262
 - protocol amendment 94
 - proton pump 48
 - inhibitor 48
 - Public Health Services (PHS) 14
- q**
- qualification
 - design (DQ) 225
 - installation IQ) 225
 - operational (OQ) 225
 - performance (PQ) 225
 - quality (Q) 2, 38
 - air 219
 - assurance (QA) system 22, 69, 179, 197, 212ff.
 - biotech product 68
 - control (QC) 215ff.
 - full QA 197
 - management system 170
 - module 101
 - pharmaceutical QA system principle 218
 - system inspection technique (QSIT) 248f.
 - system regulation (QSR) 180, 231ff.
- r**
- reference drug exclusivity 159
 - registration
 - veterinary medicinal product (VICH) 39
 - regulation 1ff.
 - directive 210
 - legal framework 3
 - EU 210
 - US 159, 211
 - regulatory body 27
 - regulatory strategy 21ff.
 - report
 - correction 273
 - expedited 255ff.
 - periodic 262
 - reporting requirement 254
 - US 258
 - reproductive toxicology study 67
 - requirement 207
 - good manufacturing practice (GMP) 212
 - reporting 254ff.
 - review process
 - EU 114ff.
 - US 124ff.
 - risk 2, 207
 - analysis 184
 - analysis matrix 228
 - rules governing medicinal products in the European Union 79
- s**
- safety (S) 38
 - safety pharmacology study 66
 - safety study report 256
 - scientific evaluation process 119
 - self-inspection 223
 - single-blind trial 77
 - site master file 239
 - special drug application 149
 - sponsor 80

- stability 104
 - study 68
- standard 168
- standard operating procedure (SOP) 24
- statistical power 77
- Steering Committee 38f.
- stent 18
- sterilisation procedure
 - validation 230
- submission 114ff.
 - 510(k) 204
 - EU 114
 - US 124
- summary 107ff.
 - product characteristics (SPC) 110, 143, 258
- supplementary NDA/NADA 156
- suspected unexpected serious adverse reaction (SUSAR) 87ff.

- t**
- teratogen 67
- test
 - *in-vitro* test with mammalian cell 66
 - *in-vivo* test in rodent 66
- therapeutic effect
 - speed and duration 53f.
- therapeutic use 45
- toxicokinetics 62
- toxicity
 - acute lethal 65
 - study 65
- toxicology study 65
- traditional herbal remedy 16
- trial, *see also* clinical trial
 - end 88
 - master file 88
 - monitoring 88
 - protocol 81

- u**
- United States Pharmacopoeia (USP) 7, 36
- United States [of America] (US)
 - clinical trial 89ff., 135
 - core good manufacturing practice (GMP) 214
 - Department of Agriculture (USDA) 35
 - drug producer registration 241
 - evaluation 191
 - medical device regulatory strategy 173
 - medical device vigilance 271
 - module 113
 - producer of drug/device registration 241
 - registration of person 240
 - reporting requirement 258
 - review process 124ff.
 - submission 124
 - veterinary medicine 144
- US regulation 159, 211
 - OTC drug 162

- v**
- vaccine antigen master file 124
- validation 26, 223ff.
 - sterilisation procedure 230
- verification 26
- veterinary biological establishment
 - license 147
- veterinary biological product 147
 - approval 147
- Veterinary International Conference on Harmonisation (VICH) 131
- veterinary medicine 129ff.
 - approval 144
 - authorisation 129ff.
 - development process 129
 - EU 138
 - US 144
- VICH (veterinary medicinal product)
 - harmonisation process 40
- vigilance 237ff.

- w**
- water purification system 220
 - validation 230
- World Health Organization (WHO) 42
- work contracted out 222f.

- z**
- zidovudine 47

